MODE 1: Pre-Acquisition Deep Analysis (收购前深度分析)
Section 3: Financial Deep Dive (财务深度分析)
Project Tengen | IASO Bio × Medisix Therapeutics Date: 2026-03-20 | Classification: CONFIDENTIAL
3.1 Historical Financial Forensics (历史财务取证分析)
3.1.1 Income Statement Trend Analysis [Source: EY FDD Report]
| Metric | FY2022 | FY2023 | FY2024 | 9M FY2025 | Trend |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | No commercial revenue |
| R&D Expenses | ~$6.5M (est.) | $5.19M | $3.28M | $1.94M | ↓ Declining 37%/yr — cash conservation |
| G&A Expenses | ~$2.0M (est.) | $2.13M | $2.16M | $1.60M | → Stable (~$2.1M/yr) |
| Total OpEx | ~$8.5M | $7.32M | $5.44M | $3.54M | ↓ Declining — forced cost-cutting |
| Net Loss | ~$(8.5M) | $(7.21M) | $(5.36M) | $(3.54M) | ↓ Narrowing due to cuts, not improvement |
| Headcount (avg) | ~30 (est.) | 28 | ~15 (est.) | 5 | ↓ 82% reduction in 2 years |
💡 INSIGHT: The declining loss trajectory is NOT a sign of improving business health — it reflects severe cash conservation through headcount reduction (28→5 employees) and suspension of 6 out of 8 R&D programs. This is a company in managed wind-down mode, not operational optimization.
3.1.2 Cumulative R&D Investment by Program [Source: EY FDD]
| Program | Cumulative Spend | % of Total | Status |
|---|---|---|---|
| PCART7 (anti-CD7 autologous) | $17.68M | 60.3% | Active (Phase I/II) |
| AlloPCART7 (allogeneic) | $1.21M | 4.2% | Active (early clinical) |
| PCART3 (anti-CD3) | $1.53M | 5.3% | Suspended |
| 5 other projects | ~$8.93M | 30.2% | All Suspended |
| Total R&D since inception | $29.35M | 100% | — |
3.1.3 Quality of Earnings Analysis
Normalization adjustments required:
| Item | Amount | Classification | Notes |
|---|---|---|---|
| Campana consulting fees (reinstated 2023) | $300K/yr | Recurring operating | Deferred from 2021-2023; now ongoing |
| Andrew Bruce compensation (CEO→consultant) | ~$200K/yr (est.) | Semi-recurring | Changed from employee to consulting Dec 2025 |
| Intercompany R&D services (cost + 7%) | ~$2-3M/yr | Related party | 7% markup at bottom of arm's length range (6.66-30.50%) |
| Patent maintenance costs | ~$600K/yr ($50K/month) | Recurring operating | Non-discretionary to maintain IP portfolio |
| TMC Pharma regulatory services | Variable | Project-based | ~EUR 18.5K for EU SME services |
| OPBG clinical study costs | ~EUR 1.7M commitment | Project-based | Contractual obligation for 36-patient study |
Normalized annual operating cost (going concern basis): ~$4.5-5.5M/year (pre-manufacturing rebuild)
3.1.4 Working Capital Normalization
| Item | FY2023 | FY2024 | Sep 2025 | Notes |
|---|---|---|---|---|
| Cash | $5.67M | $1.19M | $80,333 | Critical — below 1 month's operations |
| Trade receivables | $0 | $0 | $0 | No revenue |
| Trade payables | ~$0.5M (est.) | ~$0.3M (est.) | ~$0.2M (est.) | Limited vendor base |
| Accrued liabilities | — | — | — | Campana deferred fees from 2017-2023 period |
| Net working capital | ~$5.2M | ~$0.9M | ~$(0.1M) | Negative NWC by Sep 2025 |
3.1.5 Capex: Maintenance vs Growth
| Category | Amount | Notes |
|---|---|---|
| Lab equipment (original cost) | $1.50M | 37 items |
| Lab equipment (book value Sep 2025) | $496K | Depreciated |
| Maintenance capex | ~$50K/yr (est.) | Minimal — lab equipment |
| Growth capex | $0 | No new investments since cash crisis |
3.1.6 Hidden Liabilities Screen
| Liability | Amount | Status | Source |
|---|---|---|---|
| CPNs (Convertible Promissory Notes) | $24.54M + accrued interest | Non-current at MT Inc (USA); guaranteed by MT SG | EY FDD |
| 2025 Bridge Notes | $2.85M at 8% compound | Maturity Mar 31, 2026 | EY FDD |
| InterCompany Loan | ~$12M | Interest-free, unsecured, on-demand; transfer pricing exposure | ArrowGates |
| OPBG clinical study commitment | ~EUR 1.7M | 36-patient study contractual obligation | Internal Eval |
| NUS milestone payments | Up to SGD 1.75M cumulative | IND, Phase 3, marketing authorization milestones | NUS License |
| NUS royalties | 1.5-2.5% of net sales | Future obligation on commercialization | NUS License |
| NUS equity participation | Up to 10% / $10M | Right to invest; may be triggered by acquisition | NUS License |
| WuXi outstanding commitments | $77K | Stability testing and TMC Pharma | EY FDD |
| IP attorney fees | $89-301K/quarter through 2028 | Patent prosecution and maintenance | EY FDD |
| Campana consulting fees | $300K/year to Apr 2028 | Contractual obligation | Founder Agreement |
| Poste director fees | $50K/year | Until termination | Director Agreement |
| Bruce consulting fees | GBP 1K/day, max 2 days/week | 2-year term from Dec 2025 | Consulting Agreement |
| Stock options outstanding | 14,125,588 options | 2019 Stock Incentive Plan | EY FDD |
| Potential transfer pricing adjustment | Unknown | $12M intercompany loan + 7% R&D markup at low end of range | ArrowGates |
| Deferred Campana fees (2017-2023) | Unknown | Amendment 2 deleted consulting fees; unclear if arrears exist | Founder Agreement |
Total identified/estimated liabilities: $40-45M+
🔴 RED FLAG: The total liability burden ($40-45M+) likely exceeds the intrinsic value of the assets in a distressed sale scenario. The acquirer's thesis MUST be that the platform value under IASO's stewardship far exceeds the cleanup cost.
3.2 Valuation (估值分析)
3.2.1 DCF Valuation
Methodology: Risk-adjusted NPV (rNPV) approach appropriate for clinical-stage biopharmaceutical company with no revenue.
Key Assumptions:
| Parameter | Value | Justification |
|---|---|---|
| WACC | 12% | Clinical-stage biotech; cross-border risk; small company premium |
| Terminal growth rate | 2% | Long-term pharma industry growth |
| Explicit forecast period | 15 years | Through patent expiry of core assets |
| Tax rate | 17% (SG) / 25% (CN) | Blended based on operating structure |
| Probability of success by stage | Phase I/II: 40-50% (PCART7); Preclinical: 8-15% (others) | Industry benchmarks adjusted for data quality |
DCF / rNPV Summary:
| Scenario | PCART7 | AlloPCART7 | CD99 | CD70 | Platform | Total Enterprise Value |
|---|---|---|---|---|---|---|
| Bull | $72M | $43M | $48M | $64M | $80M | $307M |
| Base | $28M | $16M | $18M | $22M | $30M | $114M |
| Bear | $8M | $4M | $4M | $5M | $10M | $31M |
| Probability-weighted | $120M |
Probability weights: Bull 20%, Base 60%, Bear 20%
Net of liabilities:
| Item | Amount |
|---|---|
| Probability-weighted enterprise value | $120M |
| Less: CPN/debt restructuring | $(30M) |
| Less: InterCompany loan cleanup | $(5M) est. tax cost |
| Less: Manufacturing rebuild | $(12M) |
| Less: Regulatory/clinical investment needed | $(8M) |
| Implied equity value to current shareholders | $65M |
3.2.2 Comparable Company Analysis
True comparables are scarce — Medisix is a pre-revenue, clinical-stage, single-platform company in a niche indication. Closest peers:
| Company | Stage | Technology | EV | EV/Pipeline Asset | Notes |
|---|---|---|---|---|---|
| Wugen (private) | Pivotal Phase 2 | CRISPR CD7 CAR-T | ~$500M (implied by $115M raise) | ~$250M/asset | Most advanced CD7 competitor; BTD, RMAT, PRIME |
| Poseida Therapeutics (acquired) | Phase I/II | piggyBac CAR-T platform | $1.5B (Roche) | ~$300M/asset | Platform premium; allogeneic + autologous |
| 2seventy bio (acquired) | Commercial (Abecma) | Lentiviral CAR-T | $286M (BMS) | ~$286M (single asset) | Distressed; $406M Abecma revenue |
| ICell Gene (private) | Phase I | Non-editing CD7 CAR-T | Unknown | — | Earlier stage |
| PersonGen (private, China) | Phase I/II | PEBL-like CD7 nanobody | Unknown | — | China-focused |
Adjustment factors for Medisix:
| Factor | Adjustment | Rationale |
|---|---|---|
| Stage discount (Phase I/II vs pivotal) | -50% vs Wugen | Wugen is 2+ years ahead in regulatory |
| Platform premium | +30% vs single-asset | PEBL extensible to multiple targets |
| Distress discount | -40% | Near-insolvency; 4 employees; no manufacturing |
| Geographic/size discount | -20% | Singapore-based; tiny team; no US presence |
| Data quality premium | +15% | 94-100% MRD-neg CR; Nature Medicine publication |
Implied comparable valuation range:
| Approach | Low | Mid | High |
|---|---|---|---|
| Wugen discount (50-70% of $500M) | $150M | $200M | $250M |
| Poseida discount (5-15% of $1.5B) | $75M | $150M | $225M |
| 2seventy premium (platform > single asset) | $100M | $200M | $350M |
| Median implied EV | $175M |
Less distress adjustments:
- Net of liabilities (~$45M): $130M implied equity value
- Further distress discount (30-50%): $65-90M implied equity value
3.2.3 Precedent Transactions
| Transaction | Date | Value | Metric | Relevance |
|---|---|---|---|---|
| Roche / Poseida | Nov 2024 | $1.5B ($1.0B upfront + $0.5B CVR) | Platform + clinical assets (allogeneic CAR-T) | Most relevant platform deal; 215% premium |
| BMS / 2seventy bio | Mar 2025 | $286M ($102M net of cash) | Commercial CAR-T (Abecma, $406M rev) | Distressed asset; 88% premium |
| Novartis / Kate Therapeutics | 2024 | $1.1B | Gene therapy platform | Platform premium comparable |
| MilliporeSigma / Mirus Bio | 2024 | $600M | Manufacturing/platform technology | Manufacturing capability valued |
| Gilead-Kite / Shoreline | Cancelled 2025 | Originally $2.3B | Allogeneic CAR-T | Deal cancelled — reflects sector uncertainty |
| Yifan Pharma / SciGen (SG) | 2018 | ~$28M | SG biotech; biosimilar portfolio | China-SG precedent but different stage |
Implied metrics from precedent transactions:
- Platform acquisition range: $75M-$1.5B
- Pre-revenue clinical-stage with platform: $75-300M
- Distressed pre-revenue with platform (Medisix-like): $30-100M
3.2.4 Sum-of-the-Parts Valuation
| Component | Valuation Method | Value (Base) | Value (Bull) |
|---|---|---|---|
| PCART7 (Phase I/II, CD7 T-ALL) | rNPV | $28M | $72M |
| AlloPCART7 (early clinical) | rNPV | $16M | $43M |
| CD99-PEBL (preclinical, expert-validated) | rNPV | $18M | $48M |
| CD70-PEBL (preclinical) | rNPV | $22M | $64M |
| PCART3 (preclinical, suspended) | rNPV | $4M | $10M |
| PEBL platform option value | Real options | $30M | $80M |
| NUS exclusive license value | License comparables | $10M | $25M |
| OPBG clinical relationship | Strategic value | $5M | $15M |
| Fixed assets (lab equipment) | Book value | $0.5M | $0.5M |
| IP portfolio (116 patents) | Cost approach | $5M | $15M |
| Gross asset value | $138.5M | $372.5M | |
| Less: Total liabilities | $(45M) | $(40M) | |
| Net equity value | $93.5M | $332.5M |
3.2.5 Football Field Summary (估值区间汇总)
Valuation Methodology Low Mid High
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
DCF / rNPV |===[$31M]=========[$120M]=========[$307M]===|
Comparable Companies |====[$65M]========[$130M]=======[$250M]====|
Precedent Transactions |==[$30M]========[$75M]========[$300M]======|
Sum-of-the-Parts |====[$93M]=========[$175M]========[$333M]=|
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
$0M $50M $100M $150M $200M $300M+
RECOMMENDED RANGE (equity): ████████[$50M]══════[$80M]██████████
Central estimate: $50-80M equity value (net of liabilities)
This reflects:
- Base-case rNPV of $120M enterprise value
- ~$40-45M in total liability cleanup
- 20-30% negotiation discount for distressed seller
- Significant upside optionality from platform expansion (CD99, CD70)
3.2.6 Sensitivity Analysis
Sensitivity to PCART7 probability of success:
| PoS for PCART7 CMA | Equity Value (Base) |
|---|---|
| 30% | $58M |
| 40% | $71M |
| 45% (base case) | $78M |
| 50% | $85M |
| 60% | $99M |
Sensitivity to platform expansion success (CD99 + CD70 combined PoS):
| Platform Expansion PoS | Equity Value (Base) |
|---|---|
| 5% | $52M |
| 10% (base case) | $78M |
| 15% | $104M |
| 20% | $130M |
| 30% | $182M |
💡 INSIGHT: Equity value is MORE sensitive to platform expansion success than to PCART7 alone. A 10-percentage-point increase in platform expansion PoS adds ~$52M in value, while the same increase in PCART7 PoS adds only ~$28M. This confirms the thesis that the platform is the primary value driver.
3.2.7 Implied Acquisition Premium Analysis
| Metric | Value |
|---|---|
| Total funding raised (Medisix) | ~$50M |
| Last round implied valuation (est.) | ~$100-150M (pre-money, 2021 Series C) |
| Current "fair value" given distress | $20-40M (forced sale/liquidation) |
| Recommended offer range | $50-80M equity value |
| Premium to distressed fair value | 25-300% |
| Discount to last round valuation | 33-67% |
3.3 Deal Economics (交易经济性分析)
3.3.1 Sources and Uses of Funds
Sources:
| Source | Amount (Est.) | Notes |
|---|---|---|
| IASO cash on balance sheet | $30-50M | RMB 207.5M revenue; RMB 1.87B total assets |
| IASO C2 round proceeds | $15-30M | RMB 215M raised Sep 2025 |
| Potential bridge financing | $10-20M | If needed for integration capex |
| Total sources | $55-100M |
Uses:
| Use | Amount (Est.) | Timing |
|---|---|---|
| Base acquisition price (equity) | $15-30M | At closing |
| CPN restructuring/novation | $22-30M | At or before closing |
| Bridge note repayment | $3M | At closing (maturity Mar 2026) |
| InterCompany loan cleanup | $2-5M | At closing |
| Transaction costs (legal, advisory, tax) | $3-5M | At closing |
| Earnout/milestone reserve | $10-20M | Over 3-5 years |
| Total uses | $55-93M |
3.3.2 Pro Forma Balance Sheet Impact (IASO Bio)
| Item | IASO Standalone (FY2024) | Post-Acquisition Impact |
|---|---|---|
| Total assets | RMB 1.87B | +$50-80M in intangible assets (PEBL platform, NUS license, clinical data) |
| Cash | — | -$40-60M (acquisition + liability cleanup) |
| Goodwill | — | +$20-40M (premium over identifiable assets) |
| Total liabilities | — | +$5-10M (assumed obligations) |
| Net asset impact | — | Net negative $20-30M in Year 1 |
3.3.3 Return Analysis
IRR and MOIC under scenarios:
| Scenario | 5-Year Exit Value | Total Investment | IRR | MOIC |
|---|---|---|---|---|
| Bull (PCART7 CMA + CD99 success) | $500M | $80M | 44% | 6.3x |
| Base (PCART7 CMA; CD99/CD70 in clinical) | $200M | $75M | 22% | 2.7x |
| Bear (PCART7 delayed; platform value only) | $80M | $70M | 3% | 1.1x |
| Downside (clinical failure; IP salvage only) | $30M | $65M | -14% | 0.5x |
Exit value = implied enterprise value at Year 5 based on pipeline stage and comparable valuations
3.3.4 Breakeven Analysis
What must be true for value creation (MOIC > 1.0x):
- PCART7 must achieve CMA in Europe OR IND in US — establishes regulatory proof and platform credibility (probability: 45-55%)
- At least one expansion target (CD99 or CD70) must reach IND stage — demonstrates platform versatility beyond CD7 (probability: 20-30%)
- Manufacturing chain must be rebuilt at cost ≤ $12M — exceeding this erodes returns (probability: 70%)
- Campana must remain engaged for ≥ 3 years — without him, expansion targets stall (probability: 75% with proper retention)
- NUS license must remain in good standing — license termination would be catastrophic (probability: 90% with proactive management)
Combined breakeven probability: ~25-35%
💡 INSIGHT: While the combined breakeven probability appears modest, the highly skewed return profile (6.3x bull vs 0.5x downside) means expected value is positive. This is a classic venture-style bet appropriate for a company like IASO that already has a profitable commercial product and can absorb the downside.
[All source citations refer to documents indexed in 00_Document_Inventory.md]